Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101635493 | 10163549 | 3 | F | 2012 | 20160913 | 20140509 | 20160922 | EXP | PHHY2014MX054965 | SANDOZ | 0.00 | F | Y | 0.00000 | 20160922 | MD | MX | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101635493 | 10163549 | 1 | SS | GALVUS MET | METFORMIN HYDROCHLORIDEVILDAGLIPTIN | 1 | Oral | 2.5 DF (1 MORNING, 1 NIGHT AND HALF IN AFTERNOON), QD | 0 | 2.5 | DF | TABLET | QD | ||||||
| 101635493 | 10163549 | 2 | SS | GALVUS MET | METFORMIN HYDROCHLORIDEVILDAGLIPTIN | 1 | Oral | 1 DF, QD | 0 | 1 | DF | TABLET | QD | ||||||
| 101635493 | 10163549 | 3 | SS | GALVUS MET | METFORMIN HYDROCHLORIDEVILDAGLIPTIN | 1 | Oral | 2 DF, QD (500/50 MG) | 0 | 2 | DF | TABLET | QD | ||||||
| 101635493 | 10163549 | 4 | SS | GALVUS MET | METFORMIN HYDROCHLORIDEVILDAGLIPTIN | 1 | Oral | 2.5 DF (500 MG METF/ 50 MG VILD), DAILY (ONE IN MORNINGS AND NIGHTS AND A HALF IN AFTERNOON) QD | S0496 | 0 | 2.5 | DF | TABLET | QD | |||||
| 101635493 | 10163549 | 5 | SS | GALVUS MET | METFORMIN HYDROCHLORIDEVILDAGLIPTIN | 1 | Oral | 3 DF, QD (500/50 MG) | 0 | 3 | DF | TABLET | QD | ||||||
| 101635493 | 10163549 | 6 | PS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | UNK | Y | 75985 | |||||||||
| 101635493 | 10163549 | 7 | C | EXFORGE | AMLODIPINE BESYLATEVALSARTAN | 1 | Oral | STARTED 3 MONTHS AGO | 0 | ||||||||||
| 101635493 | 10163549 | 8 | C | EUTIROX | LEVOTHYROXINE SODIUM | 1 | Unknown | U | 0 | ||||||||||
| 101635493 | 10163549 | 9 | C | AVIX | 2 | Unknown | U | 0 | |||||||||||
| 101635493 | 10163549 | 10 | C | VESSEL DUE-F | 2 | Unknown | U | 0 | |||||||||||
| 101635493 | 10163549 | 11 | C | LANOXIN | DIGOXIN | 1 | Unknown | 0.25 MG, UNK | U | 0 | .25 | MG | TABLET | ||||||
| 101635493 | 10163549 | 12 | C | AXIS | 2 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 101635493 | 10163549 | 1 | Glucose tolerance impaired |
| 101635493 | 10163549 | 6 | Product used for unknown indication |
| 101635493 | 10163549 | 7 | Blood pressure increased |
| 101635493 | 10163549 | 8 | Product used for unknown indication |
| 101635493 | 10163549 | 9 | Product used for unknown indication |
| 101635493 | 10163549 | 10 | Product used for unknown indication |
| 101635493 | 10163549 | 11 | Cardiac failure |
| 101635493 | 10163549 | 12 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 101635493 | 10163549 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 101635493 | 10163549 | Blood glucose increased | |
| 101635493 | 10163549 | Blood triglycerides abnormal | |
| 101635493 | 10163549 | Cardiac failure | |
| 101635493 | 10163549 | Diabetes mellitus inadequate control | |
| 101635493 | 10163549 | Dizziness | |
| 101635493 | 10163549 | Drug prescribing error | |
| 101635493 | 10163549 | Hypertension | |
| 101635493 | 10163549 | Incorrect dose administered | |
| 101635493 | 10163549 | Product use issue | |
| 101635493 | 10163549 | Wrong technique in product usage process |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 101635493 | 10163549 | 3 | 2012 | 0 | ||
| 101635493 | 10163549 | 4 | 201401 | 0 |